Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Anti-Cancer Agent(AG60), Anti-Hepatitis, Anti-Fibrotic Agent, Anti-BPH Agent, Anti-Hypertensive & Cholesterol Lowering Agent, Anti-Cataract Agent_Medvill
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Anti-Atopic Dermatitis Cosmetics, Anti-Acne Cosmetics, Anti-Oxidants Vitaplus...
Contact Yong U Kim
Participants
You
Email me a copy of this message

Products in Company Pipeline


 






Product






Description






Anti-cancer agent


(AG60) --- chemicals


 






•      Patent registration:  Korea and US


•       Pre-clinical studies approval; KFDA(Korean Food and Drug Administration (IND)


- Mode of Action:


•        Inhibition of tumor cell proliferation


•        Suppression of transcription factors (NF-kB and AP-1)


•        Anti-angiogenesis


•        Induction of apoptosis






Anti-hepatitis, anti-fibrotic agent - plant extract


 






- Patent registered in Korea


- Patents are pending in China and Japan


  China is a big market (60% of population is infected with hepatitis B virus)


- Efficacy:


•       Inhibition of liver fibrosis


•       Anti-viral activities against Hepatitis B virus and Hepatitis C virus (in a several human cases)


- Mode of action:   


 Inhibition of TGF-b expression


Inhibition of collagen synthesis (type-I)


  Anti-viral activity:


Anti-inflammatory activity


  Immuno stimulating activity






Anti-BPH agent






- Patents resistered in Korea and US


- Patents are pending in UK, France and Gernamy


- Efficacy:


    Anti-inflammatory activity: carrageenin paw-edema test


    Analgesic effect: acetic acid writhing test, tail-flick test


    No lowering effect on blood pressure (in 12 weeks treatment in rats)  in therapeutic dose in man


    Effective in benign prostate hyperplasia (BPH), chronic prostatitis, etc.


- Mode of action:


     Inhibition of a-receptor


     Inhibition of smooth muscle contraction: prostate and urethra specific activity (organ specificity )


     No effects on smooth muscles in stomach and bladder (muscarinic organ)     






Anti-hypertensive & cholesterol lowering agent






Patents registered in Korea and US


- Right for Utility model in Germany had been registered


- Efficacy:


    Lowering high blood pressure in SHR (Spontaneous Hypertensive Rat)


    Lowering blood cholesterol


    Lowering blood TG


    Improvement of HDL/LDL Ratio     


   - Mode of action :


     angiotensin converting enzyme inhibitor


     Calcium channel blocker






Anti-cataract agent






- Patent is registered in Korea and US.


Efficacy:


   - ex vivo test:  Effects on diabetic cataract (xylose induced cataract) in the organ culture by 50% suppression of the cloudy density.


  -  in vivo test: Inhibition of the cataract formation in diabetic rats. (oral administration for 12 weeks)


Mode of action:


  - Inhibition of aldose reductase (causing the increase in the osmolarity and in the oxicative stress of lens):    IC50 value = 11.3 mg/ml


  - Anti-oxidant activity: chemiluminescent oxidation reaction and better antioxidant effects confirmed as compared with vitamine C






 


 


Product in the market


 






Product






Description






Anti-acne


cosmetics






l  Anti-inflammatory and anti-biotic activity in cell & animal model


l  Solutions for symptoms of Acne


l  Inhibition of Propionibacterium acnes


l  Including components for the removal of dead cells in epidermal layer


l  Differentiation of DDS (Day & Night Program) 


l  Natural products in worldwide cosmetics DB


l  Patent filed


l  Safety was confirmed






Anti-atopic dermatitis


cosmetics


 






l  used non-steroidal plant extract with outstanding efficacy to control the allergy and prevent the skin dry.


l  stabilizing mast cells and prevent the secretion of histamine from mast cells.


 

FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development REGISTERED / FINISHED PRODUCT
GOVERNMENT INSTITUTE